[go: up one dir, main page]

AU2003239197A1 - Novel stable anti-cd22 antibodies - Google Patents

Novel stable anti-cd22 antibodies

Info

Publication number
AU2003239197A1
AU2003239197A1 AU2003239197A AU2003239197A AU2003239197A1 AU 2003239197 A1 AU2003239197 A1 AU 2003239197A1 AU 2003239197 A AU2003239197 A AU 2003239197A AU 2003239197 A AU2003239197 A AU 2003239197A AU 2003239197 A1 AU2003239197 A1 AU 2003239197A1
Authority
AU
Australia
Prior art keywords
antibodies
stable anti
novel stable
novel
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003239197A
Other versions
AU2003239197A8 (en
Inventor
Michaela Arndt
Jurgen Krauss
Susanna Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of AU2003239197A1 publication Critical patent/AU2003239197A1/en
Publication of AU2003239197A8 publication Critical patent/AU2003239197A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003239197A 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies Abandoned AU2003239197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38730602P 2002-06-07 2002-06-07
US60/387,306 2002-06-07
PCT/US2003/018201 WO2003104425A2 (en) 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies

Publications (2)

Publication Number Publication Date
AU2003239197A1 true AU2003239197A1 (en) 2003-12-22
AU2003239197A8 AU2003239197A8 (en) 2003-12-22

Family

ID=29736288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003239197A Abandoned AU2003239197A1 (en) 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies

Country Status (2)

Country Link
AU (1) AU2003239197A1 (en)
WO (1) WO2003104425A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60236450D1 (en) 2001-09-26 2010-07-01 Us Health MUTATED ANTI-CD22 ANTIBODIES WITH INCREASED AFFINITY TO CD22-EXPRESSIVE LEUKEMIA CELLS
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
EP2345723A1 (en) 2005-03-25 2011-07-20 National Research Council Of Canada Method for isolation of soluble polypeptides
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
RU2730594C2 (en) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Method of producing a polypeptide heteromultiters
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
NZ772550A (en) 2018-08-30 2025-08-29 Immunitybio Inc Multi-chain chimeric polypeptides and uses thereof
KR20210069639A (en) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. Single-chain chimeric polypeptides and uses thereof
CN120267819A (en) 2018-08-30 2025-07-08 免疫生物公司 Methods for treating senile related disorders
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
CN115362169A (en) 2020-02-11 2022-11-18 Hcw生物科技公司 Chromatographic resins and their uses
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4486368A1 (en) 2022-03-02 2025-01-08 ImmunityBio, Inc. Method of treating pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2003104425A2 (en) 2003-12-18
AU2003239197A8 (en) 2003-12-22
WO2003104425A3 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
AU2003219277A1 (en) Intracellular antibodies
AU2003239197A1 (en) Novel stable anti-cd22 antibodies
AU2003217912A1 (en) Antibody optimization
AU2003239909A1 (en) Enhanced-service provision
AU2002335152A1 (en) Robot-phone
AU2003275546A1 (en) Heat-schrinkable film
AU2002367810A1 (en) Bis-transition-metal-chelate-probes
AU2002368348A1 (en) Electrosomatogram
AU2002318053A1 (en) Suplier
AU2002950855A0 (en) Materials
AU2002348964A1 (en) Snowbike
AU2002341221A1 (en) Honey-brandy
AU2002344387A1 (en) Multifunction-pillow
HK1087130A (en) Antibodies
AU2002100957A4 (en) Sluggit
AU2002100160A4 (en) Oxidirator
AU2002100508A4 (en) Photocard
AU2002100510A4 (en) Bottlenecker
AU2002100541A4 (en) Backmate
AU2002100602A4 (en) Bonsystem
AU2002100655A4 (en) Armamulch
AU2002100739A4 (en) Neuramax
AU2002100747A4 (en) Powersell
AU2002100482A4 (en) Tail-gate-ezy
AU2002100026A4 (en) Disc400

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase